Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gimeracil/oteracil/tegafur/folinic acid - Taiho Pharmaceuticals

Drug Profile

Gimeracil/oteracil/tegafur/folinic acid - Taiho Pharmaceuticals

Alternative Names: Folinic acid/S-1; Gimeracil/oteracil potassium/tegafur/calcium folinate; Gimeracil/oteracil potassium/tegafur/folinic acid; Gimeracil/oteracil/tegafur/calcium folinate; Gimeracil/oteracil/tegafur/leucovorin; S-1/folinic acid; TAS 118

Latest Information Update: 28 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Chemoprotectants; Chemosensitisers; Formyltetrahydrofolates; Furans; Pyridines; Pyrimidinones; Small molecules; Triazines; Vitamins
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastric cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2019 Chemical structure information added
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (PO)
  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Pancreatic cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top